Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

With Deeming Rule Pending, FDA Reminds E-Cigarette Firms About Drug Claims

This article was originally published in The Tan Sheet

Executive Summary

In a proposed rule, FDA describes to a new audience its long-established policy on drugs and devices marketed for off-label indications. The agency says “some ambiguity surrounds the circumstances” that determine whether a product is regulated as tobacco or as a drug, device or combination product


Related Content

US-Canada Pilot Could Help FDA's OTC Monograph Update Fly
E-Cigarette ‘Deeming’ Rule In OMB Review As Health Groups Urge Claim Enforcement
FDA Floats Broader Pathway For Nicotine Replacement Therapies
In Brief
Smoking Cessation Claims For E-Cigarettes Draw FDA Warnings